Ignite Creation Date:
2025-12-25 @ 2:29 AM
Ignite Modification Date:
2025-12-26 @ 7:08 PM
Study NCT ID:
NCT07294534
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-19
First Post:
2025-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Sponsor:
Shanghai Henlius Biotech
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-01-27
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-02-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-12-08
First Submit QC Date:
None
Study First Post Date:
2025-12-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-08
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED